Product Description
A novel, oral, systemically delivered LANCL2 agonist,for the treatment of rheumatoid arthritis (Sourced from: https://ir.landosbiopharma.com/news-releases/news-release-details/landos-biopharma-announces-fda-clearance-its-ind-labp-104-0)
Mechanisms of Action: LANCL2 Activator
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: NImmune Biopharma
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Healthy Volunteers
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT05019950 |
LABP-104-1a | P1 |
Completed |
Healthy Volunteers |
2022-04-28 |
88% |
2023-06-09 |
Primary Endpoints |